Welcome to our dedicated page for ProKidney news (Ticker: PROK), a resource for investors and traders seeking the latest updates and insights on ProKidney stock.
ProKidney Corp (NASDAQ: PROK) is a clinical-stage biotechnology leader developing autologous cellular therapies for chronic kidney disease. This page provides centralized access to official company announcements, clinical trial updates, and strategic developments.
Investors and researchers will find timely updates on PROK's REACT therapy progress, including Phase 3 trial results, regulatory interactions with the FDA/EMA, and manufacturing advancements. Our news collection features earnings reports, partnership announcements, and scientific presentations - all essential for understanding the company's position in regenerative medicine.
The repository includes:
- Clinical trial milestones and data readouts
- Regulatory submissions and designations (including RMAT status)
- Financial performance updates
- Strategic collaborations in nephrology research
- Peer-reviewed study publications
Bookmark this page for verified updates about ProKidney's innovative approach to preserving kidney function through cellular therapy. Check regularly for new developments in this rapidly evolving therapeutic area.
ProKidney Corp. (Nasdaq: PROK) is hosting a virtual KOL event on May 28, 2024, to discuss the treatment landscape for chronic kidney disease (CKD) caused by diabetes. The event will feature experts Steven G. Coca and Arnold L. Silva, who will address the unmet medical needs and the importance of preserving kidney function in patients with moderate to severe CKD. The event will also cover final data from the RMCL-002 Phase 2 trial of ProKidney's lead product candidate, rilparencel (REACT®), which will be presented at the European Renal Association (ERA) Congress on May 25, 2024. A live Q&A session will follow the presentations.
ProKidney Corp. reported business updates and financial results for Q1 2024, highlighting upcoming clinical trial data presentations, leadership team enhancements, and financial performance. The Company ended the quarter with $329 million in cash and securities to support operations into Q4 2025. Notably, ProKidney aims to advance its therapeutic options for CKD patients with upcoming Phase 3 trials and a strong focus on preserving kidney function in high-risk populations.
FAQ
What is the current stock price of ProKidney (PROK)?
What is the market cap of ProKidney (PROK)?
